default author photo

Eleanor Barnes

University of Oxford - Peter Medawar Building for Pathogen Research

South Parks Road

OX2 3SY

United Kingdom

SCHOLARLY PAPERS

5

DOWNLOADS

865

TOTAL CITATIONS

4

Scholarly Papers (5)

1.

Safety, Tolerability, and Immunogenicity of NeomiVac, a Next-Generation mRNA–Lipid Nanoparticle Vaccine Comprising a Novel Ionisable Lipid: A First-In-Human, Phase 1, Dose-Escalation Trial

Number of pages: 1 Posted: 28 Jan 2026
University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford, University of Oxford, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, University of Oxford, University of Oxford - The Jenner Institute, Neovac Ltd, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford - Peter Medawar Building for Pathogen Research and University of Oxford - Oxford Vaccine Group
Downloads 492 (144,435)

Abstract:

Loading...

mRNA vaccine, novel lipid nanoparticle vaccine (LNP), reactogenicity, immunogenicity, SARS-CoV2

2.

Poor Antibody Responses to SARS-CoV-2 Infection or Vaccination Are Associated With High Re-Infection Rates in Haemodialysis and Renal Transplant Patients

Number of pages: 20 Posted: 13 Oct 2021
University of Oxford - Transplantation Research and Immunology Group, University of Oxford, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, The Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, Newcastle University - Translational and Clinical Research Institute Immunity and Inflammation Theme, Newcastle University - Translational and Clinical Research Institute, University of Birmingham - Institute of Cancer and Genomic Sciences, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, University of Liverpool - NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Oxford, University of Oxford, University of Oxford, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, University of Oxford, University of Oxford - Nuffield Department of Surgical Sciences, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Wellcome Trust Centre for Human Genetics and University of Oxford - Nuffield Department of Clinical Medicine
Downloads 151 (491,334)

Abstract:

Loading...

SARS-CoV-2, Haemodialysis, transplant, end-stage renal disease, vaccine, re-infection

3.

Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial

Number of pages: 50 Posted: 10 Nov 2023
University of Glasgow, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London, University of Glasgow, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, Sheffield Teaching Hospitals NHS Foundation Trust, Southampton University, University of Birmingham, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham - Institute of Cancer and Genomic Sciences, University of Oxford - Wellcome Trust Centre for Human Genetics, The Francis Crick Institute, Francis Crick Institute - Cell Biology of Infection Laboratory, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham - Institute of Immunology and Immunotherapy, University of Birmingham, University of Oxford - Nuffield Department of Medicine, University of Oxford, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, University of Leeds, Guy's Hospital - British Society of Blood and Marrow Transplantation and Cellular Therapy, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham, University of Saint Etienne - Centre Hospitalier Universitaire de Saint-Étienne, University of Oxford, University College London - Research Department of Hematology, University of Leicester - Leicester General Hospital, University of London - Institute of Infection and Immunity, Royal Free Hospital, University of Southampton - University Hospital Southampton NHS Foundation Trust, University of Glasgow - College of Medical, Veterinary & Life Sciences, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Imperial College Healthcare NHS Trust, University of Oxford - Nuffield Department of Medicine, University of Southampton - University Hospital Southampton NHS Foundation Trust, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Glasgow - College of Medical, Veterinary & Life Sciences, Imperial College London, Imperial College London, University of Birmingham, University of Glasgow and University of Birmingham - NIHR Birmingham Biomedical Research Centre and Institute of Cancer and Genomic Sciences
Downloads 130 (569,079)

Abstract:

Loading...

COVID-19, Immunology, Clinical trial, Vaccine

4.

ACE2 Inhibition ELISA Is an Effective Surrogate for SARS-CoV-2 Live Virus Neutralisation

Number of pages: 17 Posted: 29 Sep 2025
University of Oxford - Pandemic Sciences Institute, University of Oxford, affiliation not provided to SSRN, University of Saint Etienne - Centre Hospitalier Universitaire de Saint-Étienne, University of Oxford - Peter Medawar Building for Pathogen Research and University of Oxford - Wellcome Trust Centre for Human Genetics
Downloads 57 (989,921)

Abstract:

Loading...

SARS-CoV-2, ACE2 competition ELISA, neutralising antibodies, vaccine efficacy, immunobridging, variants of concern, COVID-19

5.

Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study

Number of pages: 56 Posted: 08 Aug 2022
University of Liverpool - Institute of Infection, Veterinary and Ecological Sciences, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Wellcome Trust Centre for Human Genetics, World Health Organization (WHO), University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, University of Birmingham - Clinical Immunology Service, University of Birmingham - Institute of Cancer and Genomic Science, University of Oxford - Pandemic Sciences Institute, University of Liverpool - NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, Newcastle University - Translational and Clinical Research Institute Immunity and Inflammation Theme, University of Liverpool - NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford - Wellcome Trust Centre for Human Genetics, NHS Foundation Trust - Liverpool University Hospitals NHS Foundation Trust (LUH), Newcastle University - Translational and Clinical Research Institute Immunity and Inflammation Theme, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, Dept Infection, Immunity & Cardiovascular Disease, University of Sheffield, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, Dept of Infectious Diseases & Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Newcastle Upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Birmingham - Institute of Immunology and Immunotherapy, University of Cambridge - MRC Toxicology Unit, University of Cambridge - MRC Toxicology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Liverpool - Institute of Infection, Veterinary and Ecological Sciences, University of Oxford - Wellcome Centre for Human Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, Sheffield Teaching Hospitals NHS Foundation Trust, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), Newcastle University - Translational and Clinical Research Institute Immunity and Inflammation Theme, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge - MRC Toxicology Unit, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, Public Health England Colindale, Newcastle University - Translational and Clinical Research Institute, University of Birmingham - Institute of Cancer and Genomic Sciences, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, University of Oxford - Nuffield Department of Clinical Medicine, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, University of Liverpool - NIHR Health Protection Research Unit for Emerging and Zoonotic Infection and Independent
Downloads 35 (1,263,436)
Citation 4

Abstract:

Loading...

SARS-CoV-2, COVID-19, COVID vaccine, T cells, antibody, immunity